美国Fate Therapeutics
位于圣地亚哥的Fate Therapeutics公司成立于2007年下半年，现在已经引进了Jaenisch和Scripps研究所的Sheng Ding成为其科学领军人物。2009年四月，该公司宣布了与Stemgent公司的合伙事宜，后者是一家干细胞试剂公司，在波士顿和圣地亚哥两地设立了两个总部，专门向生物技术公司和制药公司提供诱导多能干细胞技术和诱导多能干细胞衍生的成熟细胞，用于毒理学检测和初步的药物筛选。公司的总裁兼CEO Paul Grayson说，目前，Fate公司处于一种“具有可持续性但不具有盈利性”的状态，但是在三至七年中，他希望能将公司的第一个治疗药靶推向市场，它很可能与血液系统疾病有关。

Founded in 2007 on the leading stem cell and developmental biology research, Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics. The company has brought together the foremost scientists from the nation’s research hotbeds (Boston, San Francisco, San Diego and Seattle) who have demonstrated the potential to create and modulate stem cells to restore health.

While embryonic stem cells opened the possibility for regenerative medicine, Fate Therapeutics is focusing on adult stem cells and induced pluripotent stem (iPS) cells.

Adult stem cells naturally exist in tissues or organs and are responsible for maintaining and repairing the tissue in which they are found.
iPS cells are stem cells created from fully mature differentiated cells, like a skin cell, and promise to be of great use for drug discovery and development and personalized cell replacement therapies.
Fate is using conventional drug discovery and iPS cell technology to identify small molecules and biologics to develop therapeutics for diseases and conditions that currently have limited to no treatment options.